Cambridge, Massachusetts – home to Harvard and MIT – was the primary source of Chinese researchers who chose to head home.

Robert F. Kennedy Jr, the new U.S. health secretary, has promised to address an epidemic of chronic illness with President Donald Trump's backing, but his broad agenda from making food healthier to ...

The pound has risen to its highest value this year as the US Treasury said the Trump administration is considering currency ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

Moderna missed earnings forecasts, posting a net loss of $1.1 billion, or $2.91 per share, 23% below the expectations of analysts polled by Visible Alpha. Revenue was 4% higher than forecasts ...

Earnings season continues, and we're here to spotlight the companies expected to report their financial results on the next ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to drive future growth. Super Micro Computer rises sharply, Nvidia sells ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.